Dopamine D2-agonist cabergoline increases brain-derived neurotrophic factor mRNA expression in the rat midbrain and demonstrates anxiolytic-like behavioural effects

2017 ◽  
Vol 27 ◽  
pp. S648
Author(s):  
P. Anokhin ◽  
T. Proskuryakova ◽  
V. Shokhonova ◽  
I. Shamakina
Keyword(s):  
Mrna Expression ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Dopamine D2 ◽  
D2 Agonist ◽  
Behavioural Effects ◽  
Dopamine D2 Agonist

The effect of B-HT 920, a dopamine D2 agonist, on bar-press feeding in the monkey

1994 ◽  
Vol 55 (6) ◽  
pp. 1125-1130 ◽  
Author(s):  
Shuji Aou ◽  
Masaharu Mizuno ◽  
Tetsuro Hori ◽  
Katsushi Yamada
Keyword(s):  
Dopamine D2 ◽  
D2 Agonist ◽  
Dopamine D2 Agonist

Excitation by talipexole, a dopamine D2 agonist, of caudate nucleus neurons activated by nigral stimulation

Life Sciences ◽  
1994 ◽  
Vol 54 (14) ◽  
pp. 957-966 ◽  
Author(s):  
Naoyuki Todo ◽  
Toshihiko Momiyama ◽  
Taku Amano ◽  
Yasuko Kohno ◽  
Masashi Sasa
Keyword(s):  
Caudate Nucleus ◽  
Dopamine D2 ◽  
D2 Agonist ◽  
Dopamine D2 Agonist

scholarly journals Behavioral effects of cabergoline, a dopamine D2 agonist, on MPTP-induced parkinsonism in cynomolgus monkeys.

1994 ◽  
Vol 64 ◽  
pp. 172
Author(s):  
Nobuhiko Arai ◽  
Masayuki Isaji ◽  
Hiroshi Miyata ◽  
Eiji Mizuta ◽  
Sadako Kuno
Keyword(s):  
Behavioral Effects ◽  
Cynomolgus Monkeys ◽  
Dopamine D2 ◽  
D2 Agonist ◽  
Dopamine D2 Agonist

No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial

2015 ◽  
Vol 28 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Ulla Knorr ◽  
Pernille Koefoed ◽  
Mia H. Greisen Soendergaard ◽  
Maj Vinberg ◽  
Ulrik Gether ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Whole Blood ◽  
Neurotrophic Factor ◽  
Messenger Rna ◽  
Randomised Trial ◽  
Significant Negative Correlation ◽  
Brain Derived Neurotrophic Factor ◽  
Healthy Individuals ◽  
Bdnf Mrna ◽  
Significant Difference

ObjectiveBrain-derived neurotrophic factor (BDNF) seems to play an important role in the course of depression including the response to antidepressants in patients with depression. We aimed to study the effect of an antidepressant intervention on peripheral BDNF in healthy individuals with a family history of depression.MethodsWe measured changes in BDNF messenger RNA (mRNA) expression and whole-blood BDNF levels in 80 healthy first-degree relatives of patients with depression randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks.ResultsWe found no statistically significant difference between the escitalopram and the placebo group in the change in BDNF mRNA expression and whole-blood BDNF levels. Post hoc analyses showed a statistically significant negative correlation between plasma escitalopram concentration and change in whole-blood BDNF levels in the escitalopram-treated group.ConclusionThe results of this randomised trial suggest that escitalopram 10 mg has no effect on peripheral BDNF levels in healthy individuals.

Sign in / Sign up

Export Citation Format

Share Document